Park, C., Cho, H., Choi, Y., Oh, I., & Kim, Y. (2021). A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. Cancer Res Treat.
Citação norma ChicagoPark, Cheol-Kyu, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, and Young-Chul Kim. "A Phase II Trial of Osimertinib As the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1." Cancer Res Treat 2021.
MLA CitationPark, Cheol-Kyu, et al. "A Phase II Trial of Osimertinib As the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1." Cancer Res Treat 2021.